Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
|Articles|June 17, 2023
News Roundup: June 12 to June 16
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
How the Workplace Can Impact Respiratory Health
A recent study examined the effects that different work environments can have on adults with asthma.
Biosimilar Infliximab Not Shown to Cause Adverse Outcomes in Patients With IBD
Hesitation from patients and providers to switch to an infliximab biosimilar may not be necessary, new study finds.
Tapinarof Cream 1% Shows Positive Topline Results for Treatment of Pediatric Atopic Dermatitis
According to Dermavant, tapinarof cream 1% is a novel, aryl hydrocarbon receptor agonist in development as a once-daily topical cream.
CGM Use May Lead to Behavioral Modifications in Adolescent T2D
Generative AI Framework Could Help Create Better Medicine Faster
G2Retro, developed by investigators from Ohio State University, can produce hundreds of new reaction predictions in just a few minutes.
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
3
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5